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’ INTRODUCTION
Breast cancer is the second most frequently diagnosed
cancer among women in the United States. It is estimated that
207 090 new cases of invasive and 54 010 new cases of in situ
breast cancers occurred in females in the US in 2010.1 Early
detection is crucial to reduce the death rate of breast cancer, yet
the symptoms are not obvious in many cases. Body ﬂuids, such
as plasma or serum are good sources of biomarkers, and
therefore, eﬀorts to develop blood-based biomarker tests for
early detection of breast cancer continue to be actively
pursued.
The mining of low abundance proteins as biomarkers remains
challenging due to the large dynamic range of the blood
proteome (∼10101012 or greater2). Because the complexity
of the unfractionated proteome exceeds the capability of any
single proteomics method, multidimensional separations could,
if sample loss is limited, greatly enhance the proteome coverage.
Glycosylation is one of the most common protein post-
translational modiﬁcations, and the characterization of glycan
structures is expected to broaden the scope of discovery studies
beyond the protein level, and thus improves the clinical values of
existing biomarkers. Due to the importance of glycosylation from
cellular proliferation to angiogenesis and metastasis,3 the devel-
opment and application of techniques and methodologies for
enriching or fractionating the glycoproteome has become an
emerging ﬁeld. Lectins have been widely used in various
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ABSTRACT: The discovery of breast cancer associated plasma/serum biomarkers is
important for early diagnosis, disease mechanism elucidation, and determination of
treatment strategy for the disease. In this study of serum samples, a multidimensional
fractionation platform combined with mass spectrometric analysis were used to achieve
the identiﬁcation of medium to lower abundance proteins, as well as to simultaneously
detect glycan and abundance changes. Immuno-aﬃnity depletion and multi-lectin
chromatography (M-LAC) were integrated into an automated HPLC platform to
remove high abundance protein and fractionate glycoproteins. The collected glyco-
proteomes were then subjected to isoelectric focusing (IEF) separation by a digital
ProteomeChip (dPC), followed by in-gel digestion and LCMS analysis using an
Orbitrap mass spectrometer. As a result, the total number of identiﬁed proteins
increased signiﬁcantly when the IEF fractionation step was included as part of the
platform. Relevant proteins with biological and disease signiﬁcance were observed and
the dynamic range of the serum proteome measurement was extended. In addition,
potential glycan changes were indicated by comparing proteins in control and cancer
samples in terms of their aﬃnity to the multi-lectin column (M-LAC) and the pI
proﬁles in IEF separation. In conclusion, a proteomics platform including high
abundance protein depletion, lectin aﬃnity fractionation, IEF separation, and LCMS analysis has been applied to discover
breast cancer-associated proteins. The following candidates, thrombospondin-1 and 5, alpha-1B-glycoprotein, serum amyloid
P-component, and tenascin-X, were selected as promising examples of the use of this platform. They show potential abundance and
glycan changes and will be further investigated in future studies.
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glycoproteomic studies, such as chromatography,4 array5,6 and
blotting studies.7 We have previously demonstrated the use of a
multi-lectin aﬃnity chromatography (M-LAC) technique to
comprehensively capture glycoproteins from biological ﬂuids.8,9
A recently reported improved format, namely high-performance
multi-lectin aﬃnity chromatography (HP-MLAC),10 has been
applied in this study.
Isoelectric focusing (IEF) separates proteins based on their
isoelectric points and has advantages including high resolution
and modest cost.11 Separation based on pI diﬀerences is
valuable for the study of protein post translation modiﬁcations
(PTM) such as glycosylation and phosphorylation.12 The
resolving power of IEF in a proteomics study has been demon-
strated by many research groups. For example, Dr. Speicher’s
laboratory used a four-dimensional strategy including solution
IEF (MicroSol-IEF) starting with 2.4 μL serum, resulting in the
identiﬁcation of 575 and 2890 proteins within 140 fractions
from plasma and serum, respectively.12 Nowadays, there are
several commercially available platforms, such as the Agilent
OFFGEL fractionator, the Bio-Rad Rotofor system, the Invi-
trogen ZOOM IEF fractionator and the Cell Biosciences Digital
ProteomeChip (dPC).13 We analyzed the depleted and multi-
lectin fractionated serum (glyco)proteome derived from healthy
and breast cancer patients by the solution phase IEF fractionation
system using the dPC. The dPC is a recently introduced technique
that uses parallel IEF14 and gel plugs for rapid (30 or 45 min) and
reproducible separation of complex protein or peptide mixtures. It
is also an IEF technique that is compatible with the downstream in-
gel digestion and LCMS analysis. We recently reported on the
use of the dPC system to detect glycosylation changes by
comparing the pI proﬁles of high-medium abundance glycopro-
teins and the integration with other analytical methods including
1D SDS-PAGE, LCMS proteomic analysis and antibody-lectin
arrays.7 In this report, we describe the application of the dPC to
fractionate breast cancer and control serum samples, resulting in
the identiﬁcations of a number of low abundance or disease related
(glyco)proteins from 10 IEF fractions starting with 50 μL serum.
’EXPERIMENTAL SECTION
Serum Samples. Five serum samples from patients with
breast cancer stage 2 and another five from healthy individuals
were provided by Dr. Samir Hanash’s laboratory at the Fred
Hutchinson Cancer Center; age and race were matched between
healthy and patient individuals; all samples have been collected
with IRB approval. Individual serum was pooled to give one
control and one disease samples to minimize individual varia-
bility. Five lung cancer serum samples with matched age and
gender were purchased from ProteoGenex. All the samples were
stored at 75 C and did not undergo more than two freeze/
thaw cycles. For the purpose of method development, 10 normal
female sera were purchased from Bioreclamation (Jericho, NY)
and pooled as one reference serum sample, which was subse-
quently aliquoted and stored at 75 C.
High Abundance Protein Depletion and Glycoprotein
Fractionation. The pooled serum was fractionated using the
automated HPLC sample preparation platform, previously devel-
oped in our laboratory,10 with some minor modifications. In this
study, abundant protein removal (albumin and immunoglobulins
G, M, A, E, D and free light chains) was accomplished using
CaptureSelect depletion resins (BAC. B.V, Naarden, The Nether-
lands). The anti-albumin and anti-immunoglobulin beads were
gravity packed into an omnifit glass column (10 20 mm and 6.6
 20mm, respectively). The flow through from the CaptureSelect
depletion column was fractionated online using a high perfor-
mance multilectin affinity chromatography (M-LAC) into an
unbound (unretained proteins) and a bound (retained proteins)
fractions. The lectin column consists of mixtures of lectins con-
canavalin A (ConA), jacalin (JAC) and wheat germ agglutinin
(WGA). The details of this fractionation are described in the
Supporting Information. The unbound and bound M-LAC frac-
tions were collected and further fractionated using Isoelectric
Focusing (IEF).
Isoelectric Focusing (IEF) Analysis using Digital Proteo-
meChips (dPC).The total amount of protein loaded on the dPC
chip was first optimized. For this purpose, different amount of
M-LAC bound proteins (10, 20, 30, 50, 80, and 110 μg) derived
from healthy human serum were applied to a dPC (Cell
Biosciences, Inc., Santa Clara, CA). Sample preparation and
separation in IEF are described in the Supporting Information.
LC-MS.Clinical samples were analyzed by LTQ-Orbitrap linear
ion trap hybrid mass spectrometer (ThermoFisher Scientific,
Waltham, MA). The nano-LC separation was performed using
an Eksigent 1Dþ nano-LC system (Dublin, CA). The LCmethod
for the separation of digested peptides is described in the
Supporting Information. In mass spectrometry analysis, the ion
isolation width was 2 m/z; Orbitrap FullMS target value was 1
106; Ion trap MSn target value was 1  104. Xcalibur MS
acquisition software (Xcalibur 2.0.7, ThermoFisher Scientific)
was used for MS/MS analysis in data dependent mode. The scan
cycle includes a full scan MS acquisition in profile mode at the
resolution of 60K over the range of 4001800 m/z, followed by
up to 5 data-dependent MS/MS scans. Parameters in dynamic
exclusion were set as follows: repeat count, 1; repeat duration, 30 s.;
exclusion list size, 100; exclusion list duration, 45 s; exclusion mass
width, 0.55 m/z low and 1.55 m/z high. The activation of parallel
operation of LTQ andOrbitrap was achieved by the FTMS preview
scan. Only þ2 and þ3 peptides were interrogated by MS/MS.
Bioinformatics and the Selection for Protein Candidates.
MS/MS spectra were searched against the human database using
the Mascot software (Matrix Sciences).15 The parameters for
search were set as follows: carbamidomethylation (C) as fixed
modification; maximum missed cleavage sites was 1; mass values
were using monoisotopic peaks; peptide and fragment mass
tolerances were (5 ppm and (0.8 Da, respectively; monoiso-
topic peaks with one 13C were taken into account. Peptides with
p values smaller than 0.005 and scores higher than 25 were
considered. Decoy database searching was also included to
evaluate the false positive rate (FPR). The resulting peptide list
of each fraction was uploaded onto Mass Spec Results Analysis
Tool (MSRAT) Bioinformatics Software (Cell Biosciences, Inc.,
Santa Clara, CA) for the comparison of the pI profiles between
control and disease samples. Criteria used to select protein
candidates can be found in the Supporting Information.
ELISA of Tenascin-X (TN-X). Serum TN-X was measured by
a sandwich type ELISA. Five control and five breast cancer serum
samples were used in this ELISA study. They are the same
samples that were pooled together and used in the discovery
stage. Affinity purified rabbit antibodies against recombinant
TN-X FNIII repeats 27 to 32 were used for antigen capture.
These antibodies recognize several C-terminal fragments and
full length TN-X that present in human serum.16 The secondary
antibody of the ELISA was raised in guinea pig, against
recombinant protein from the C-terminal 100 kDa portion of
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TN-X, which comprises FNIII repeats 2732 and the fibrino-
gen-like domain. As there are fragments of many different sizes
(presumable splice forms or breakdown products) present in
human serum, no meaningful figure can be given for the total
TN-X concentration in serum. For this reason, a calibration
curve of recombinant TN-X FNIII repeats 27 to 32 was used.
The TN-X serum levels given here are equivalent to ng/mL of
this recombinant TN-X preparation. The ELISA is highly
specific, as the amount of TN-X detected is zero in serum
derived from patients that are homozygous for TN-X null
alleles.17 In addition, this ELISA does not detect tenascin-C,
another member of the tenascin gene family.
’RESULTS AND DISCUSSION
Description of the Proteomic Analysis Workflow. As
indicated in the workflow in Figure 1, high abundance protein
depletion was used as the first dimension; lectin fractionation and
IEF were applied as the second and the third dimensions,
respectively. As indicated in the workflow in Figure 1. The
contribution of the depletion and lectin fractionations to increase
the number of protein identification and overall sensitivity has
been demonstrated in previous publications.18,19 Approximately
80% of the high abundance protein representing albumin and
immunoglobulins were initially removed by two immunodeple-
tion columns. To capture the serum glycoproteins comprehen-
sively, a mixture of lectins (ConA, WGA and JAC) with affinity
for a broad range of different glycan structures (mannose,
glucose, N-acetylgalactosamine in O-linked glycan, sialic acid
and N-acetylglucosamine) was used. The specificity and repro-
ducibility of this multi-lectin column has been demonstrated in a
previous publication.10 The glycoproteins with strong specificity
toward the M-LAC column were retained as the bound fraction
and later eluted at low pH; nonglycosylated proteins and
glycoproteins with low levels of binding to the multi-lectin
column were collected as the unbound fraction. After the
removal of albumin and immunoglobulins, the remaining serum
proteins distributed inM-LAC unbound and bound fractions at a
ratio of about 1:1 (w/w).
As shown in Figure 1, the M-LAC unbound and bound
proteomes were subsequently subjected to further fractionation
using the digital ProteomeChip (dPC). Chips with operating
ranges of pH 4.206.20 and pH6.008.00 were used to separate
proteins into 82 gel plugs with a pH 0.05 variation between
adjacent plugs.We then combined the gel plugs into ten fractions
(Figure 1) for in-gel digestion and LCMS analysis. As a
Figure 1. Diagram of the workﬂow used for the analysis of the breast cancer and control sera. The strategy consists of four separation approaches—
depletion, glycoprotein fractionation, IEF fractionation using dPC and RP-LCMS peptide separation. Gel plugs in yellow were chosen for dPC
capacity study (Figure S-1, Supporting Information). Analysis platform with or without IEF separation is deﬁned as dPC(þ) or dPC() approach,
respectively.
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negative control, M-LAC fractions without dPC separation were
also subjected to trypsin digestion and LCMS analysis, which
was deﬁned as the dPC() approach. The dPC(þ) platform is
able to “mine” the (glyco)proteome with the advantage of
additional information about potential glycan alterations as
described below. In addition, the loading capacity has been
optimized to be 50 μg (Figure S-1, Supporting Information)
and the reproducibility of the dPC has been demonstrated
(Figure S-2, Supporting Information). As for the throughput of
the platform, the fractionation for a single sample was accom-
plished in approximately 80min (40min for depletion andmulti-
lectin chromatography; 30 or 45 min for IEF separation). For
convenience, trypsin digestion was performed overnight. The
LCMS analysis of the resulting peptides from one IEF fraction
required 4 h including peptide separation, blank and equilibra-
tion. Thus, compared to other platforms commonly used in the
discovery stage, our approach compares well in terms of time
required for sample depletion, glycan fractionation and IEF or
ion exchange separation.
Further Fractionation using dPC for Higher Confidence in
Protein Identification. The improved performance of our
serum proteomics platform with incorporation of the dPC
system, dPC(þ), is shown in Table 1 by the identification of a
selection of 15 abundant serum proteins with an increased
detection signal (spectral count) in comparison with the dPC-
() system. Also, the observed proteins were detected with
increased sequence coverage (data not shown), which resulted in
a higher confidence of protein identification. As can be seen from
the table, about half of the proteins were observed with a 10-fold
or more increase in spectral count. For example, the spectral
counts of pregnancy zone protein are 2186 vs 208 in dPC(þ) vs
dPC(). The detailed list of each identified peptides for the
selected proteins and their corresponding hit values are reported
in Table S-1. In addition, it is found that the number of
miscleaved peptides were much smaller in the dPC(þ) than in
the dPC() approach (approximately a 23 fold reduction),
whichmay lower the false positive rate in protein identification. A
possible explanation is that the reduced proteome complexity
resulting from the dPC separation step could allow an improved
performance for the trypsin digestion step.
Demonstration of Deeper Mining of the Proteome/Gly-
coproteome using Combined M-LAC and dPC Fractiona-
tions. The value of a combination of the first two steps, namely
abundance protein depletion and M-LAC has been reported
earlier.10 The improved performance of the dPC(þ) system
Table 1. Comparison of dPC(þ) and dPC() Approaches in Terms of Total Protein Hits
Protein description dPC(þ)a dPC()a
Alpha-2-antiplasmin 376 22
Angiotensinogen 472 14
Biotinidase 64 2
Ceruloplasmin 2927 181
Fibronectin 2657 100
Heparin cofactor 2 492 11
Histidine-rich glycoprotein 542 68
Insulin-like growth factor-binding protein complex acid labile chain 257 9
Interalpha-trypsin inhibitor heavy chain H2 1158 94
Interalpha-trypsin inhibitor heavy chain H3 206 6
Kallistatin 192 8
Lipopolysaccharide-binding protein 110 3
Pregnancy zone protein 2186 208
Serum paraoxonase/arylesterase 1 281 10
Zinc-alpha-2-glycoprotein 284 11
aThe sum of spectral counts in duplicate runs.
Figure 2. Number of proteins identiﬁed in the M-LAC (A) bound and
(B) unbound fractions with and without IEF further separation. This
analysis is based on proteins with more than one unique peptide.
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which includes all three fractionation steps is shown in Figure 2.
The total protein identification numbers are 216 vs 128 and
190 vs 55 as dPC(þ) vs dPC() in M-LAC bound (Figure 2A)
and unbound (Figure 2B) fractions, respectively. In addition, 11
and 30 additional proteins unique to the breast cancer proteome
were identified with our dPC (þ) approach in the bound and
unbound fraction, respectively.
As is shown in Table 2 and Table S-2-1 (Supporting In-
formation), a signiﬁcant number of lower level proteins were
identiﬁed in the serum samples collected from breast cancer and
healthy individuals and these proteins were not detected in the
absence of the dPC step. Lower level proteins that were identiﬁed
with 23 unique peptides and spectral counts of greater than 2
are shown in Table 2 (also see Table S-2-1 for proteins identiﬁed
with 410 unique peptides, as well as the identiﬁed peptides for
each protein in detail, Supporting Information). Since we used
stringent criteria (p < 0.005) to ﬁlter peptides after the database
search (see the Experimental section), the identiﬁed peptides are
with relatively high mass accuracy (ΔPPM is 2.44 on average).
Hence, we have also reported on proteins with one peptide
identiﬁcation in Table S-2-2 (Supporting Information). In addi-
tion, the MS2 spectra of these peptides have been examined
manually to ensure a conﬁdent identiﬁcation. Further evidence
for the deeper mining ability of the dPC(þ) platform is demon-
strated by the detection of the low abundance secreted proteins
and potential tissue leakage fragments. According to protein
annotations in Swiss-Prot,20 the subcellular locations of proteins
in Tables 2 and S-2-2 (Supporting Information) include secreted,
membrane, cytoplasm, Golgi, peripheral membrane, cell surface,
nucleus etc. The presence of proteins in serum samples which
have a non secreted classiﬁcation can be explained by mechan-
isms, such as alternatively spliced forms, the cleavage of
plasma membrane associated proteins by proteases21 and
damage-associated molecular pattern (DAMP) in cell turn
over.22 Secreted proteins account for 34% and 15% as shown
in Table S-2-1 (proteins with 210 unique peptides) and
Table S-2-2 (proteins with 1 total peptide), respectively. In
addition, some of the secreted proteins listed in Tables 2 and
S-2-2 have been studied using ELISA by other laboratories and
demonstrated to be of low abundance. For example, periostin,
tenascin-X and vascular cell adhesion protein 1 have been
reported to be 21.0 ( 7.3 ng/mL,23 476 ( 117 ng/mL17 and
574.2( 42.7 ng/mL.24 In the future study, the detection range
could be further extended by depleting more high abundance
Table 2. Proteins Identiﬁed with 2-3 Unique Peptides (Spectral Count >1) through Depletion-(M-LAC)-dPC(þ)-MS Approach
spectral countb
Protein description Swiss-Prot acc. no. SLa unique total ΔPPMc scorec
Annexin A1 P04083 N, C, M 2 2 0.72 67
14-3-3 protein epsilon P62258 C 2 2 1.18 61
Beta-actin-like protein 2 Q562R1 C 2 2 2.93 41
A disintegrin and metalloproteinase with thrombospondin motifs 13 Q76LX8 S 2 2 1.94 67
Creatine kinase M-type P06732 C 2 2 0.70 79
Integrin beta-1 P05556 M 2 2 0.86 28
Tropomyosin beta chain P07951 C 2 2 1.88 45
Caspase-14 P31944 C, N 2 2 3.35 34
Structural maintenance of chromosomes protein 3 Q9UQE7 N 2 3 2.43 30
4F2 cell-surface antigen heavy chain P08195 M 2 5 3.31 42
SH3 domain-binding glutamic acid-rich-like protein 3 Q9H299 C, N 2 6 4.14 57
Filaggrin-2 Q5D862 2 7 1.46 49
Tenascin-X P22105 S 5 9 1.47 47
Serum amyloid A-4 protein P35542 S 2 11 2.35 48
Phosphoglycerate kinase 2 P07205 C 2 13 2.85 31
Selenoprotein P P49908 S 2 22 2.35 61
ATP synthase subunit beta, mitochondrial P06576 PM 2 19 2.37 59
Alpha-actinin-2 P35609 C 3 3 3.21 49
Alpha-mannosidase 2 Q16706 G, M 3 3 1.84 37
Gamma-glutamyl hydrolase Q92820 S 3 4 3.07 42
Contactin-1 Q12860 M 3 4 2.29 48
Di-N-acetylchitobiase Q01459 L 3 5 2.88 59
Neural cell adhesion molecule L1-like protein O00533 M 3 7 2.61 34
Xaa-Pro dipeptidase P12955 3 8 3.43 53
Basement membrane-speciﬁc heparan sulfate proteoglycan core protein P98160 S, M 3 8 2.79 38
Mannosyl-oligosaccharide 1,2-alpha-mannosidase IA P33908 G, M 3 9 2.60 46
Putative HLA class I histocompatibility antigen, alpha chain H P01893 M 3 14 1.92 39
Serum amyloid A protein P02735 S 3 18 3.31 47
a SL: subcellular location as annotated in Swiss-Prot.20 C = Cytoplasm; M =Membrane; G = Golgi; PM = Peripheral membrane; CS = cell surface; N =
Nucleus; ER = Endoplasmic reticulum; S = Secreted; L = Lysosome. bThe sum of spectral count from two independent mass spec observations.
cAverage ΔPPM and MASCOT Score values are shown for each protein.
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Table 3. Protein of Interest Identiﬁed through the Depletion-(M-LAC)-dPC(þ)-MS Approach
Protein description Swiss-Prot acc. no. ΔM-LACa ΔpIa Δabundancea signiﬁcance in cancerb
4F2 cell-surface antigen heavy chain P08195  þ
72 kDa type IV collagenase P08253  þ
Actin, cytoplasmic 1 P60709 þ þ
Adiponectin Q15848  þþ
Alpha-1-acid glycoprotein 2 P19652 þ þþ
Alpha-1-antichymotrypsin P01011   þþ
Alpha-1-antitrypsin P01009 þ þþ
Alpha-1B-glycoproteinc,d P04217  þþ
Alpha-2-antiplasmin P08697   þþ
Alpha-2-HS-glycoprotein P02765  þþ
Angiotensinogen P01019   þþ
Antithrombin-III P01008  þþ
Apolipoprotein B-100 P04114  þ
Biotinidase P43251  þþ
C4b-binding protein alpha chain P04003  þ
Cadherin-5 P33151  þþ
Carbonic anhydrase 1 P00915 þ þ
Cartilage oligomeric matrix protein (Thrombospondin-5, TSP5)c,e P49747 þ þþ
CD5 antigen-like O43866  þ þ
Cholinesterase P06276  þþ
Clusterin P10909   þþ
Collagen alpha-1(I) chain P02452 þ þþ
Complement C1q subcomponent subunit B P02746  þþ
Complement C1s subcomponent P09871  þþ
Complement C4-A P0C0L4 þ þþ
Complement C4B P0C0L5  þþ
Desmoglein-2 Q14126  þþ
Desmoplakin P15924 þ þþ
Di-N-acetylchitobiase Q01459  þþ
Extracellular matrix protein 1 Q16610  þþ
Glutathione peroxidase 3 P22352  þ þ
Haptoglobin P00738  þþ
Hemopexin P02790  þþ
Heparin cofactor 2 P05546  þ
Hepatocyte growth factor-like protein P26927  þ
Histidine-rich glycoprotein P04196   þþ
Hyaluronan-binding protein 2 Q14520  þ
Immunoglobulin J chain P01591 þ þ
Insulin-like growth factor-binding protein complex acid labile subunit P35858  þ
Interalpha-trypsin inhibitor heavy chain H1 P19827   þþ
Interalpha-trypsin inhibitor heavy chain H2 P19823  þ
Interalpha-trypsin inhibitor heavy chain H3 Q06033  þþ
Interalpha-trypsin inhibitor heavy chain H4 Q14624   þþ
Kallistatin P29622  þþ
Kininogen-1 P01042   þþ
Lactotransferrin P02788  þ þþ
Lumican P51884  þþ
Mannan-binding lectin serine protease 1 P48740  þ
Monocyte diﬀerentiation antigen CD14 P08571   þþ
Myosin-1 P12882  þ
Myosin-2 Q9UGM7  þ
Myosin-4 Q9UGM8  þþ
N-Acetylmuramoyl-L-alanine amidase Q96PD5  þ
Neural cell adhesion molecule L1-like protein O00533  þþ
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protein, or by pooling less dPC gel plugs to yield more
fractions for MS analysis.
Selection of Proteins of Potential Interest for Breast Cancer
Detection.One of the challenges of a clinical proteomic study is to
effectively select protein candidates for further study because down-
stream validation studies require expensive and time-consuming
developments, such as ELISA and the multiple reaction monitoring
(MRM) approach,25 on a cohort of clinical samples which are
usually difficult to obtain. In this study of the breast cancer serum
proteome with the dPC(þ) approach, a total of approximately 400
proteins were characterized and four criteria of interest were
investigated for each identified protein, namely M-LAC bind-
ing, potential pI shift, abundance change and biological/clinical
significance (detailed information is shown inTable S-3-1, S-3-2 and
S-3-3, Supporting Information). Table 3 lists a subset of ∼80
proteins from the total of 400 with an observation in at least two
of the four categories. Clearly, this number of candidates is still too
large for a follow up study and thus, we performed a further selection
based on the requirement for a significant and positive observation
in at least two categories, which includes the data present in Table
S-3-1 to S-3-3, and the protein’s cancer/biological significance (also
see Table 4). As example of this selection process, we report here on
five proteins that meet these criteria: thrombospondin-1 and 5
(TSP1 and TSP5), alpha-1B-glycoprotein (A1BG), serum amyloid
P-component (SAP) and tenascin-X (TN-X). The improved
detection limit over comparable approaches and the revealed
potential changes (abundance or/and glycan) demonstrate the
advantages of our platform including extending the dynamic range
of the proteomic measurement, as well as providing information on
glycan pattern and pI profile.
Proteins of Interest Showing Abundance Change.We will
now describe the salient features of these 5 proteins selected for
Table 3. Continued
Protein description Swiss-Prot acc. no. ΔM-LACa ΔpIa Δabundancea signiﬁcance in cancerb
Peroxiredoxin-2 P32119 þ þþ
Phosphatidylcholine-sterol acyltransferase P04180  þ
Phospholipid transfer protein P55058  þþ
Pigment epithelium-derived factor P36955  þþ
Plasma protease C1 inhibitor P05155   þþ
Plasma serine protease inhibitor P05154  þþ
Plasminogen P00747 þ þþ
Plastin-2 P13796 þ þ
Polymeric immunoglobulin receptor P01833  þþ
Pregnancy zone protein P20742  þþ
Properdin P27918  þþ
Protein AMBP P02760   þ
Protein Z-dependent protease inhibitor Q9UGM6  þþ
Prothrombin P00734  þþ
Retinol-binding protein 4 P02753   þ
Scavenger receptor cysteine-rich type 1 protein M130 Q86VB7  þþ
Serotransferrin P02787 þ þþ
Serum amyloid A protein P02735  þþ
Serum amyloid P-componentc,f P02743  þ þþ
Sex hormone-binding globulin P04278  þþ
Tenascin-Xc,g P22105 þ þþ
Thrombospondin-1 (TSP1)c,e,h P07996  þ þþ
Thyroxine-binding globulin P05543  þ
Transthyretin P02766 þ þ
Vascular cell adhesion protein 1 P19320  þþ
Vitamin K-dependent protein C P04070  
Vitamin K-dependent protein S P07225  
Vitronectin P04004  þ
Von Willebrand factor P04275  þþ
Zinc-alpha-2-glycoprotein P25311  þþ
aAM-LAC: altered binding to M-LAC;ΔpI: pI change in calculated pI vs measured pI or in dPC proﬁle breast cancer vs control samples;ΔAbundance:
abundance change. “(” refers to “increase/decrease” level. The criteria used to deﬁne an increase or decrease in level is described in the Supporting
Information. bBiological signiﬁcance in (breast) cancer is based on the listed references. “þ/þþ” indicates that the protein has been reported to be
associated with “cancer/breast cancer”, respectively. References are in Supporting Information Table S-4. c Five proteins underlined will be discussed in
detail in “Proteins of interest showing abundance change” in the “Results and discussion” section. dWas reported to exhibit a pI shift in breast cancer
serum sample.7 eTSP1 and TSP5 interact with cell surface proteins such as integrins and CD47 and glycosaminoglycans. They may play important roles
in cancer progression by enhancing the adhesion and migration of tumor cells and stromal cells. 26 f SAP is not a signiﬁcant acute-phase protein even
though it has substantial homology with C-reactive protein (CRP).27 gAn extracellular matrix glycoprotein, which regulates cell adhesion, growth and
cellular migration.28 hTSP1 is an adhesive glycoprotein that has multiple biological functions, including platelet aggregation, ﬁbrin clot formation,
cellcell/matrix contact, activation of extracellular proteases and inhibition of angiogenesis.29
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further study. Serum amyloid P-component (SAP) and throm-
bospondin-5 (TSP5 or cartilage oligomeric matrix protein) were
identified with 6 and 7 unique peptides, respectively. As shown
in Table 4, the total level of serum amyloid P-component (SAP)
and thrombospondin-5 (TSP5) were increased in the breast
cancer serum samples relative to controls based on the spectral
count measurement (in fact, TSP5 was only detected in breast
cancer serum samples). We then confirmed this observation
with the corresponding peak area measurements where we
selected two peptides for each protein based on the criteria of
a consistent IEF profiles in all samples analyzed and good S/N
ratios in the MS measurement (see Table 4 footnote c and d).
Our results are also consistent with other cancer studies: the
serum level of SAP has been reported to increase significantly in
breast cancer and its concentration is correlated with disease
stages;30 elastosis with localized SAP has been observed at a
higher level in breast carcinoma;31 the thrombospondin family
including TSP5 has also been reported to increase in malignant
breast tissue.32
Proteins of Interest Showing Potential pI Shift. While a
significant number of proteins listed in Table S-3-2 (73 proteins
of interest showing pI shift, Supporting Information) showed a
difference in measured vs theoretical pI of greater than 0.5 pH
units, we have selected alpha-1B-glycoprotein (A1BG), a known
glycoprotein, as a representative example. We observed a pI shift
to a more acidic value for A1BG in the breast cancer samples
(from fraction 3 to 2, see the peak area values with underlines in
Table 4) but with only a slight increase in total abundance in the
cancer samples. Differences in the glycan structure of A1BG has
been reported to be associated with breast cancer,33 pancreatic
cancer4 and colorectal cancer.34
Proteins of Interest Showing Different M-LAC Binding.
With thrombospondin-1 (TSP1), we have an example where
there is no concentration change (spectral count 139 vs 148,
breast cancer vs control) but a difference in M-LAC binding
where less TSP1 is bound to the M-LAC column in breast cancer
(see Table 4, in addition, the full data set is given in Table S-3-1,
Supporting Information). Such a result can be explained by a
Table 4. Spectral Count of Five Protein Candidates and Peak Area of Selected Peptides in Control and Breast Cancer Sera
aThe sum of spectral count from two independent mass spec observations. bCon: control; BC: breast cancer. c IEF fractions with the highest
concentration of each protein among the 10 IEF fractions. For example, dPC fraction #4 and #3 are the most and the second most focused fractions for
SAP, respectively. d Peak area of the selected peptide for each protein. Namely, peptide DNELLVYK, peptide NALWHTGDTESQVR, peptide
HQFLLTGDTQGR, peptide GGVNDNFQGVLQNVR and peptide LNWEAPPGAFDSFLLR identiﬁed for SAP, TSP5, A1BG, TSP1 and TN-X,
respectively. ePeak area of another selected peptide for each protein. Namely, peptide IVLGQEQDSYGGK, peptideQVCTDINECETGQHNCVPNSV-
CINTR, peptide TPGAAANLELIFVGPQHAGNYR, peptideGTSQNDPNWVVR and peptide LGPISADSTTAPLEK identiﬁed for SAP, TSP5, A1BG,
TSP1 and TN-X, respectively. fUNB: M-LAC unbound fraction; BD: M-LAC bound fraction. g vv and v/V refer to signiﬁcant increased and slight
increased/decreased level of the protein or peptide, respectively, when compare breast cancer to control case. hND means Not Detected. iOnly one
peptide of TN-X from the IEF separation was available for good quality peak area comparison.
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change in glycan structure. This observation is consistent with the
facts that TSP1 is known to be glycosylated and an abnormal
glycan structure of TSP1 has been reported in congenital disorders
of glycosylation (CDGs).35 Moreover, the association of TSP1
with breast cancer has been shown in other publications.3639
Proteins of Interest Showing Different M-LAC Binding, pI
Shift and Abundance Change. Finally, we have selected an
example, tenascin-X (TN-X), from these studies where there is
evidence for changes in concentration and glycan structure, as well
as relevant disease information. Increased levels of tenascin-X in
tumor development4042 or, more specifically, breast cancer43,44
has been reported. Although TN-X is a relatively medium level
serum protein (476 ( 117 ng/mL),17 we observed an increased
serum level of tenascin-X (TN-X) in the breast cancer pooled
sample from the spectral count measurement, as well as peak area
measurements of the identified peptides (see Table 4). Further-
more, a potentially altered glycan structure of TN-X could be
demonstrated both by different pI profiles and differential M-LAC
binding. In the dPC analysis of the unbound and bound M-LAC
fractions, TN-X was primarily focused in fraction 4 and (1 þ 2),
respectively. The level of spectral counts (36) was not sufficient
for meaningful relative concentration measurement, but the peak
area comparison did demonstrate amodestly increased level of TN-
X in breast cancer serum sample (see Table 4).
Confirmation of Proteomic Analysis of Tenascin-X (TN-X).
The next stage in a proteomic biomarker discovery, such as
described here, is to develop a high throughput assay suitable for
the clinical laboratory. At present, ELISA is the gold standard in
terms of sensitivity, reproducibility and throughput.45 The
ELISA described here is used to confirm the presence of this
protein in the serum samples and to compare the M-LAC, dPC
and MS results with an ELISA format. Hence, we performed an
ELISA for tenascin-X in small study using 5 controls and 5 breast
cancer patients. In addition, sera from 5 lung cancer patients were
included for comparative purposes. As shown in Figure 3, the
mean level of tenascin-X is somewhat increased for the ELISA
study in breast cancer compared to the control group with a fold
change of 1.4, which is consistent with the 1.3 fold change
(see Table 4) measured by our proteomic analysis. In the case of
lung cancer, the levels of tenascin-X were not increased, which is
consistent with the absence of literature reports. This small study
indicates that this antibody can be used as an assay reagent for
tenascin-X, as well as confirming the proteomic results of a
somewhat increased level of this protein in breast cancer. As we
discussed in Table 3, a protein disease marker may exhibit
changes either in concentration, glycosylation, or both. Thus,
the ELISA format which is typically based on a protein epitope
may not be sufficient. These initial results indicate the need for a
glycoproteomics measurement for a more discriminating assay,
which is based on glycan as well as protein concentration
changes. As previously published,7 we will use the lectin array
format developed by Dr. Haab to measure the glycan changes in
tenascin-X in a larger sample set of patients with breast cancer.
’CONCLUSIONS
In this study, we report on the development of a multi-
dimensional fractionation platform including high abundance
protein depletion, multi-lectin chromatography (M-LAC) se-
paration, IEF (dPC) fractionation, and LCMS/MS analysis for
the investigation of the breast cancer serum (glyco)proteome.
We have demonstrated that the dPC(þ) platform signiﬁcantly
extends the dynamic range of the serum proteomic measure-
ment. As a result, we have identiﬁed more low abundance
proteins with higher sequence coverage relative to the approach
without dPC fractionation. We have also given examples of
another advantage of this platform, in that proteins with altered
glycans can be observed to change their binding aﬃnity toward
the multi-lectin column (neutral and charged glycans), as well as
showing diﬀerent pI proﬁles in IEF (dPC) (due to the presence
of diﬀerent amounts of sialic acid). We plan to follow the
characterization study reported here, with assays suitable for
larger clinical studies, such as ELISA,MRM of the corresponding
glycopeptide and an antibody-lectin sandwich microarray to
conﬁrm these glycoprotein biomarker candidates in a signiﬁcant
group of patients in a follow up study. The steps will be
performed in a manner consistent with the goal of discovery of
biomarkers for the improved early detection for breast cancer.
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Figure 3. Levels of tenascin-X (TN-X) evaluated by ELISA. Sera from
ﬁve control (b), ﬁve breast cancer (9) and ﬁve lung cancer (2)
individuals, as well as the pool of each set (O, 0 and 4) were studied.
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